{"id":"recombinant-activated-factor-vii","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Arterial thromboembolism"},{"rate":null,"effect":"Venous thromboembolism"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2109205","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rFVIIa is a recombinant version of human coagulation Factor VIIa that binds to tissue factor (TF) on cell surfaces, initiating the extrinsic pathway of blood coagulation. This complex catalyzes the conversion of Factor X to Factor Xa, which then generates thrombin and ultimately leads to fibrin clot formation. It is used to bypass deficiencies or inhibitors in the intrinsic coagulation pathway.","oneSentence":"Recombinant Activated Factor VII (rFVIIa) directly activates the extrinsic coagulation pathway to promote thrombin generation and hemostasis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:27.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A or B with inhibitors"},{"name":"Factor VII deficiency"},{"name":"Bleeding episodes in patients with coagulation disorders"}]},"trialDetails":[{"nctId":"NCT07157423","phase":"PHASE4","title":"A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-26","conditions":"Severe Postpartum Haemorrhage","enrollment":64},{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT07227246","phase":"PHASE3","title":"Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2","status":"RECRUITING","sponsor":"Joseph Broderick, MD","startDate":"2025-05-06","conditions":"Intracerebral Hemorrhage","enrollment":350},{"nctId":"NCT03496883","phase":"PHASE3","title":"Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph Broderick, MD","startDate":"2021-12-03","conditions":"Intracerebral Hemorrhage","enrollment":860},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":55},{"nctId":"NCT07290634","phase":"","title":"Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion","status":"RECRUITING","sponsor":"Zeliha Alicikus","startDate":"2026-01-30","conditions":"Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma","enrollment":4},{"nctId":"NCT07136857","phase":"PHASE2","title":"Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-02","conditions":"Glanzmann Thrombasthenia","enrollment":6},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT05695391","phase":"PHASE3","title":"A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM","status":"TERMINATED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2024-06-07","conditions":"Hemophilia","enrollment":2},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":"Hemophilia A","enrollment":12},{"nctId":"NCT05904210","phase":"","title":"Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2023-11-07","conditions":"Hemophilia","enrollment":17},{"nctId":"NCT04595617","phase":"NA","title":"Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2021-01-06","conditions":"Glanzmann Thrombasthenia","enrollment":28},{"nctId":"NCT01561391","phase":"PHASE4","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":36},{"nctId":"NCT05487976","phase":"PHASE3","title":"Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04-28","conditions":"Hemophilia A, Hemophilia B","enrollment":50},{"nctId":"NCT04723979","phase":"","title":"NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-05-01","conditions":"Post Partum Hemorrhage","enrollment":3322},{"nctId":"NCT05298826","phase":"","title":"Recombinant Factor VII for Intractable Postpartum Haemorrhage","status":"COMPLETED","sponsor":"Aljazeera Hospital","startDate":"2019-06-01","conditions":"Post Partum Hemorrhage","enrollment":41},{"nctId":"NCT02448680","phase":"PHASE3","title":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2015-12-07","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":25},{"nctId":"NCT02548143","phase":"PHASE3","title":"LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2016-08-25","conditions":"Hemophilia","enrollment":12},{"nctId":"NCT03196284","phase":"PHASE2","title":"A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-08-10","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":26},{"nctId":"NCT02622321","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-18","conditions":"Hemophilia A","enrollment":113},{"nctId":"NCT02418793","phase":"PHASE1","title":"A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2015-05","conditions":"Hemophilia A, Hemophilia B","enrollment":27},{"nctId":"NCT01757405","phase":"PHASE3","title":"Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-02-20","conditions":"Hemophilia A, Hemophilia B","enrollment":40},{"nctId":"NCT04768699","phase":"PHASE1","title":"Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-12-01","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":24},{"nctId":"NCT03079063","phase":"PHASE3","title":"Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2017-03-01","conditions":"Factor VII Deficiency","enrollment":24},{"nctId":"NCT03935334","phase":"PHASE3","title":"Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2018-07-23","conditions":"Hemophilia A or B With Inhibitor","enrollment":48},{"nctId":"NCT04424563","phase":"","title":"Activated Factor Seven in Traumatic Retro Peritoneal Hematoma","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2017-05-05","conditions":"Traumatic Bleeding","enrollment":80},{"nctId":"NCT02919800","phase":"PHASE1","title":"A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2017-01-22","conditions":"Hemophilia A or B With Inhibitors","enrollment":32},{"nctId":"NCT02484638","phase":"PHASE2, PHASE3","title":"Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2015-07-23","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":25},{"nctId":"NCT03251547","phase":"","title":"Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2017-08-21","conditions":"Massive Hemorrhage, Massive Blood Loss, Massive Blood Transfusion; Thrombocytopenia","enrollment":76},{"nctId":"NCT01359202","phase":"PHASE2","title":"\"Spot Sign\" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy","status":"COMPLETED","sponsor":"Dr. David Gladstone","startDate":"2011-05","conditions":"Stroke","enrollment":50},{"nctId":"NCT00951405","phase":"PHASE2","title":"Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":23},{"nctId":"NCT02900690","phase":"","title":"Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2010-04-22","conditions":"Health Care Cost, Post Partum Haemorrhage","enrollment":84},{"nctId":"NCT00810888","phase":"PHASE2","title":"The Spot Sign for Predicting and Treating ICH Growth Study","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2010-11","conditions":"Intracerebral Hemorrhage","enrollment":92},{"nctId":"NCT01876745","phase":"","title":"A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-10-07","conditions":"Congenital Bleeding Disorder, Glanzmann's Disease","enrollment":4},{"nctId":"NCT02020369","phase":"PHASE3","title":"Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors","status":"COMPLETED","sponsor":"rEVO Biologics","startDate":"2014-04","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":27},{"nctId":"NCT01439971","phase":"PHASE1","title":"Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2011-12","conditions":"Hemophilia A","enrollment":29},{"nctId":"NCT02470871","phase":"PHASE1","title":"Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-07","conditions":"Congenital Coagulation Factor VII Deficiency","enrollment":9},{"nctId":"NCT01542619","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Healthy","enrollment":40},{"nctId":"NCT00486278","phase":"PHASE2","title":"Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-06","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":51},{"nctId":"NCT01564563","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2002-06-28","conditions":"Acquired Bleeding Disorder, Bleeding During/Following Surgery","enrollment":11},{"nctId":"NCT00124293","phase":"","title":"Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10-06","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":63},{"nctId":"NCT01561417","phase":"PHASE1","title":"Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Acquired Bleeding Disorder, Acquired Haemophilia, Congenital Bleeding Disorder","enrollment":28},{"nctId":"NCT00426803","phase":"PHASE2","title":"Recombinant Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":400},{"nctId":"NCT01563458","phase":"PHASE2","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-08","conditions":"Acquired Bleeding Disorder, Bleeding During/Following Surgery","enrollment":208},{"nctId":"NCT00102037","phase":"PHASE2","title":"Use of Activated Recombinant FVII in Spinal Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-07","conditions":"Acquired Bleeding Disorder, Spinal Fusion","enrollment":50},{"nctId":"NCT01562821","phase":"PHASE2","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-07","conditions":"Acquired Bleeding Disorder, Cirrhosis","enrollment":235},{"nctId":"NCT01563445","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":40},{"nctId":"NCT01563471","phase":"PHASE1","title":"Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-10","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":39},{"nctId":"NCT01563523","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-03","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":283},{"nctId":"NCT00154492","phase":"PHASE2","title":"Use of NovoSeven® in Active Variceal Bleeding","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-04","conditions":"Acquired Bleeding Disorder, Cirrhosis","enrollment":265},{"nctId":"NCT01601457","phase":"PHASE2","title":"Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":48},{"nctId":"NCT01566786","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-08","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":48},{"nctId":"NCT01562574","phase":"PHASE3","title":"Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-01","conditions":"Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass","enrollment":82},{"nctId":"NCT00123591","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":96},{"nctId":"NCT01779921","phase":"","title":"Treatment of Congenital Factor VII Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Congenital Bleeding Disorder, Congenital FVII Deficiency","enrollment":163},{"nctId":"NCT00571584","phase":"PHASE4","title":"High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":24},{"nctId":"NCT00127283","phase":"PHASE3","title":"Recombinant Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-05","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":829},{"nctId":"NCT00104455","phase":"PHASE1","title":"Dose Response to Recombinant Factor VIIa When Administered for Bleed","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06","conditions":"Congenital Bleeding Disorder, Healthy","enrollment":64},{"nctId":"NCT00108797","phase":"PHASE4","title":"Trial of NovoSeven® in Haemophilia - Joint Bleeds","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-09","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":42},{"nctId":"NCT00108758","phase":"PHASE2","title":"Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-03","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":23},{"nctId":"NCT01561352","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-09","conditions":"Other Haemostasis Disorder, Haemorrhagic Cystitis","enrollment":7},{"nctId":"NCT01562587","phase":"PHASE1","title":"Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":18},{"nctId":"NCT00154427","phase":"PHASE2","title":"Use of Activated Recombinant Human Factor VII in Cardiac Surgery","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass","enrollment":172},{"nctId":"NCT00703911","phase":"","title":"Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-03","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":102},{"nctId":"NCT01601613","phase":"PHASE2","title":"Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-07","conditions":"Acquired Bleeding Disorder, Dengue Haemorrhagic Fever","enrollment":28},{"nctId":"NCT01562158","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04","conditions":"Acquired Bleeding Disorder, Bleeding During/Following Surgery","enrollment":100},{"nctId":"NCT00882778","phase":"","title":"PROPACT: Retrospective Prophylaxis Patient Case Collection","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":86},{"nctId":"NCT00697320","phase":"","title":"Observational Study on the Efficacy and Safety of NovoSeven® During \"Real-life\" Usage in Germany","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Congenital Bleeding Disorder, Congenital FVII Deficiency, Glanzmann's Disease","enrollment":64},{"nctId":"NCT01561937","phase":"PHASE1","title":"Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01","conditions":"Haemostasis, Healthy","enrollment":127},{"nctId":"NCT01561950","phase":"PHASE1","title":"Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2008-05","conditions":"Haemostasis, Healthy","enrollment":91},{"nctId":"NCT01561924","phase":"PHASE1","title":"Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":17},{"nctId":"NCT00266006","phase":"PHASE2","title":"Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-01","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":90},{"nctId":"NCT00710619","phase":"","title":"Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":52},{"nctId":"NCT00853086","phase":"","title":"Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":139},{"nctId":"NCT00243243","phase":"PHASE3","title":"Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn","status":"COMPLETED","sponsor":"United States Army Institute of Surgical Research","startDate":"2006-01","conditions":"Burns","enrollment":20},{"nctId":"NCT00951873","phase":"PHASE1","title":"A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-07","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":38},{"nctId":"NCT00922792","phase":"PHASE1","title":"Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-06","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":8},{"nctId":"NCT01562457","phase":"PHASE1","title":"Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":30},{"nctId":"NCT01220141","phase":"","title":"Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-11","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":51},{"nctId":"NCT00370877","phase":"PHASE4","title":"rhuFVIIa in Post-partum Hemorrhage","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2007-04","conditions":"Postpartum Hemorrhage","enrollment":84},{"nctId":"NCT01476423","phase":"","title":"Observational Registry of the Treatment of Glanzmann's Thrombasthenia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-01","conditions":"Congenital Bleeding Disorder, Glanzmann's Disease","enrollment":218},{"nctId":"NCT01234545","phase":"","title":"Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-10","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":35},{"nctId":"NCT01312636","phase":"","title":"Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-03","conditions":"Congenital Bleeding Disorder, Congenital FVII Deficiency","enrollment":36},{"nctId":"NCT00184548","phase":"PHASE3","title":"Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":554},{"nctId":"NCT02084810","phase":"PHASE1","title":"Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2014-03","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors","enrollment":""},{"nctId":"NCT01285089","phase":"","title":"Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-12","conditions":"Acquired Bleeding Disorder, Acquired Haemophilia","enrollment":21},{"nctId":"NCT01352143","phase":"","title":"Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-03","conditions":"Cardiopulmonary Bypass","enrollment":24},{"nctId":"NCT01708564","phase":"PHASE1","title":"A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B","status":"COMPLETED","sponsor":"rEVO Biologics","startDate":"2012-10","conditions":"Hemophilia","enrollment":15},{"nctId":"NCT01105546","phase":"PHASE2","title":"rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2010-12","conditions":"Hemophilia A With Inhibitors","enrollment":50},{"nctId":"NCT01800435","phase":"PHASE4","title":"A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2011-10","conditions":"Hereditary Factor VIII Deficiency Disease With Inhibitor","enrollment":6},{"nctId":"NCT01269138","phase":"","title":"Treatment of Inherited Factor VII Deficiency","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2007-01","conditions":"Factor VII Deficiency","enrollment":223},{"nctId":"NCT00284193","phase":"PHASE4","title":"Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2005-01","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT00323570","phase":"PHASE3","title":"Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":""},{"nctId":"NCT00328133","phase":"","title":"The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2006-06","conditions":"Traumatic Hemorrhage, Hemorrhagic Shock","enrollment":380},{"nctId":"NCT01538160","phase":"NA","title":"A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2012-02","conditions":"Hemophilia C","enrollment":15},{"nctId":"NCT00770718","phase":"PHASE1","title":"Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-04","conditions":"Intracranial Hemorrhage","enrollment":2},{"nctId":"NCT00128050","phase":"PHASE2","title":"Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2005-01","conditions":"Intracerebral Hemorrhage","enrollment":30},{"nctId":"NCT00443573","phase":"PHASE1, PHASE2","title":"Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer","status":"SUSPENDED","sponsor":"ARCA Biopharma, Inc.","startDate":"2006-12","conditions":"Colon Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1381,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NovoSeven RT, Novo Nordisk, Bagsvaerd, Denmark","NovoSeven"],"phase":"phase_3","status":"active","brandName":"Recombinant Activated Factor VII","genericName":"Recombinant Activated Factor VII","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant activated factor VII is a protein-based treatment used to address various bleeding disorders, including intracerebral hemorrhage, congenital bleeding disorders, and hemophilia A. It works by interacting with coagulation factor IX to facilitate blood clotting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}